Chinese gene therapy startup Exegenesis completes a new round of financing

Jun 10, 2021


Exegenesis, a Chinese gene therapy company, successfully completed a Series B++ financing with tens of millions of dollars. The deal was led by Legend Capital. Investors like Temasek, Lake Bleu Capital, LYFE Capital and BioTrack Capital also followed the investment. 

The proceeds will be used to advance the clinical and research and development of the company's multiple gene therapy pipelines.

Founded in 2019, Exegenesis is an innovative pharmaceutical company dedicated to providing accessible gene therapy to the global market. And the firm’s vision is to provide an epoch-making one-time cure, safe, effective and affordable gene therapy drugs for patients.